Psychopharmacologic Drugs Advisory Committee
Meeting on December 12, 2011, from 8 a.m. to 5 p.m.
Agenda: The committee will discuss safety and efficacy issues with new drug application (NDA) 022549, ADASUVE (loxapine) inhalation powder, Alexza Pharmaceuticals, Inc., for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Particular issues for discussion are concerns regarding pulmonary safety.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment